• Publications
  • Influence
Topical treatment of early cutaneous T-cell lymphoma.
The two major topical treatment modalities for cutaneous T-cell lymphoma (CTCL) are mechlorethamine (nitrogen mustard) and topical carmustine (BCNU). Topical mechorethamine hydrochloride has beenExpand
  • 72
  • 2
Update of Carcinoembryonic Antigen Radioimmunotherapy with 131I-Labetuzumab After Salvage Resection of Colorectal Liver Metastases: Comparison of Outcome to a Contemporaneous Control Group
BackgroundWe tested whether adjuvant radioimmunotherapy (RAIT) given after R0 resection of liver metastases (LM) of colorectal cancer is safe and can improve survival. Resection of LM from colorectalExpand
  • 69
  • 2
Association between autoimmune thyroiditis and depressive disorder in psychiatric outpatients
Thyroid diseases are often associated with psychiatric disorders. The prevalence of autoimmune thyroiditis in the general population is estimated to be at about 5–14 %. A clinical study was conductedExpand
  • 20
  • 1
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with
A phase II trial evaluated safety, feasibility and efficacy of a sequential tandem approach combining myeloablative BEAM chemotherapy and autologous stem cell transplantation (ASCT) withExpand
  • 12
Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab
2545 Background: A phase I/II, multi-center, dose-escalation trial was conducted to establish the safety, optimal dosing, and preliminary efficacy of 90Y-epratuzumab administered weekly for 2 or 3Expand
  • 6
Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
2545 Background: A phase I/II, multi-center, dose-escalation trial was conducted to establish the safety, optimal dosing, and preliminary efficacy of 90Y-epratuzumab administered weekly for 2 or 3Expand
  • 2
18F-FDG-PET/CT bei erhöhten Entzündungsparametern unklarer Genese – eine Zusammenführung verschiedener Entitäten
The diagnostic strategy in patients with fever or inflammation of unknown origin remains a major clinical challenge. The aim of this study was to evaluate the role of 18F-FDG-PET/CT in patients withExpand
  • 1
Zona oftálmico de la úvea
[Intervienen: Stross, Melller, Kraemer, Marburg, Lindner. Replica del autor]. Sociedad Oftalmologica de Viena. Sesion del 17 de noviembre de 1919.